Fagron Compounding Services Vancomycin HCL Class II Recall - Sterility Concerns

Fagron Compounding Services initiated a voluntary Class II recall for Vancomycin HCL 1 gram added to 250 mL 0.9% Sodium Chloride Injection USP (NDC 71266-5082-01) after identifying sterility assurance issues and a potential defect in the blue Break-Off-Part of the administration port. The recall covers seven lot numbers totaling 11,680 bags distributed nationwide, with the firm initiating recall on March 20, 2026 and FDA classifying the recall on April 7, 2026.\n\nHealthcare providers and pharmacies that received or dispensed this product should verify their inventory against the affected lot numbers (C274-000050987, C274-000049425, C274-000050069, C274-000050346, C274-000050698, C274-000050699, C274-000050775) and follow established recall response procedures. While the recall is voluntary, Class II designation indicates reasonably be expected to cause temporary or reversible adverse health consequences, making it important for affected parties to assess patient exposure and implement appropriate mitigation measures.